Detection of mutations in CML patients resistant to tyrosine kinase inhibitor: imatinib mesylate therapy | SpringerLink
Second generation inhibitors of BCR-ABL for the treatment of imatinib- resistant chronic myeloid leukaemia | Nature Reviews Cancer
Frontiers | BCR-ABL Independent Mechanisms of Resistance in Chronic Myeloid Leukemia
Bcr-Abl tyrosine-kinase inhibitor - Wikipedia
Imatinib: Basic Results | Oncohema Key
Part I: mechanisms of resistance to imatinib in chronic myeloid leukaemia. | Semantic Scholar
Overcoming imatinib resistance in chronic myelogenous leukemia cells using non-cytotoxic cell death modulators - ScienceDirect
![PDF] Novel targeted therapies to overcome imatinib mesylate resistance in chronic myeloid leukemia (CML). | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/800ff3e36d003a19dad5dd24b03c15a74f708084/14-Figure3-1.png "PDF] Novel targeted therapies to overcome imatinib mesylate resistance in chronic myeloid leukemia (CML). | Semantic Scholar")
PDF] Novel targeted therapies to overcome imatinib mesylate resistance in chronic myeloid leukemia (CML). | Semantic Scholar
![PDF] Mechanisms of Resistance to Imatinib and Second-Generation Tyrosine Inhibitors in Chronic Myeloid Leukemia | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/0a9b23d5cd08b70bab6df94e2948ce56a8452958/6-Figure1-1.png "PDF] Mechanisms of Resistance to Imatinib and Second-Generation Tyrosine Inhibitors in Chronic Myeloid Leukemia | Semantic Scholar")
PDF] Mechanisms of Resistance to Imatinib and Second-Generation Tyrosine Inhibitors in Chronic Myeloid Leukemia | Semantic Scholar
IJMS | Free Full-Text | Mechanisms of Disease Progression and Resistance to Tyrosine Kinase Inhibitor Therapy in Chronic Myeloid Leukemia: An Update
Semi‑random mutagenesis profile of BCR‑ABL during imatinib resistance acquirement in K562 cells
Bcr-Abl and Imatinib (STI571 or Gleevec) - Proteopedia, life in 3D
shRNA Loss-of-Function Screen Identifies Alternate Pathway for BCR-ABL - Cellecta
Imatinib Pathway, Pharmacokinetics/Pharmacodynamics
Imatinib resistance in chronic myeloid leukaemia caused by Bcr-Abl kinase domain and non-Bcr-Abl mutations: a comparison and review. | Australian Medical Student Journal
Deubiquitylation of Rab35 by USP32 promotes the transmission of imatinib resistance by enhancing exosome secretion in gastrointestinal stromal tumours | Oncogene
IJMS | Free Full-Text | Mechanisms of Disease Progression and Resistance to Tyrosine Kinase Inhibitor Therapy in Chronic Myeloid Leukemia: An Update
Imatinib resistance mechanisms. Imatinib resistance can be attributed... | Download Scientific Diagram
Mechanisms of acquired resistance to tyrosine kinase inhibitors - ScienceDirect
Frontiers | Advances in the research of the mechanism of secondary resistance to imatinib in gastrointestinal stromal tumors
Mechanisms of CML cells resistance to TKI. BCR-ABL dependent mechanisms... | Download Scientific Diagram
Adaptive phenotypic modulations lead to therapy resistance in chronic myeloid leukemia cells | PLOS ONE
Imatinib Resistance and Progression of CML to Blast Crisis: Somatic Hypermutation AIDing the Way - ScienceDirect
